Search Results for: 99

— Allowance of Patent Provides Exclusive Method of Use Protection Until at Least 2034 — ROCKVILLE, Md., June 27, 2017 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a late-stage clinical company developing therapeutics that preserve the microbiome to protect and restore the health of patients, announced today that the U.S. Patent and Trademark Office […]

— FDA Action Marks First Breakthrough Therapy Designation for Clinical Program Designed to Prevent Primary Clostridium difficile Infection — — Type-B Meeting Anticipated to Discuss Potential for Expedited Drug Development Strategy — ROCKVILLE, Md., May 11, 2017 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a late-stage clinical company developing therapeutics that preserve the microbiome to

— Results from Phase 2b Proof-of-Concept Study Exploratory Endpoints Demonstrate Ribaxamase Protects and Preserves Gut Microbiome from Ceftriaxone-mediated Dysbiosis — — Two Ribaxamase and Two SYN-010 Presentations to be Included at Digestive Disease Week (DDW 2017) — — Conference Call Today, May 4, 2017, at 4:30 p.m. (EDT) — ROCKVILLE, Md., May 4, 2017 /PRNewswire/

— Study Results Further Support Advancement of SYN-005 into Clinical Trials for Treatment and Prevention of Pertussis — — Poster Presentations Planned for ECCMID and ESPID Conferences, Including Data from Prophylaxis Study — ROCKVILLE, Md., April 19, 2017 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a late-stage clinical company developing therapeutics that preserve the microbiome

— Company Highlights Clinical Successes of Late-stage Microbiome-focused Programs, Plans for Phase 3 Development — — Conference Call Today, March 2, 2017, at 4:30 p.m. (EST) — ROCKVILLE, Md., March 2, 2017 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a late-stage clinical company developing therapeutics that preserve the microbiome to protect and restore the health

— Enrollment in SYN-010 Pivotal Trial Will Be Open to All IBS-C Patients — ROCKVILLE, Md., Jan. 18, 2017 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a late-stage clinical company developing therapeutics designed to preserve the microbiome to protect and restore the health of patients, today confirmed plans to initiate a Phase 2b/3 adaptive pivotal

— Presentation Planned for 9:30am (PT), Jan. 9, 2017 at Biotech Showcase in San Francisco — ROCKVILLE, Md., Jan. 5, 2017 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a late-stage clinical company developing therapeutics that preserve the microbiome to protect and restore the health of patients, today announced positive topline data from its Phase 2b

– Granted Patent Provides Composition of Matter Protection for SYN-005 to at Least 2035 – ROCKVILLE, Md., Dec. 13, 2016 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a late-stage clinical company developing therapeutics focused on the gut microbiome, today announced that the United States Patent Office has granted U.S. Patent No. 9,512,204 which provides

ROCKVILLE, Md., Nov. 18, 2016 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a late-stage clinical company developing therapeutics focused on the gut microbiome, today announced the closing of its previously announced underwritten public offering of 25,000,000 shares of its common stock and accompanying warrants to purchase 50,000,000 shares of its common stock at a

ROCKVILLE, Md., Nov. 15, 2016 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a late-stage clinical company developing therapeutics focused on the gut microbiome, today announced the pricing of an underwritten public offering of 25,000,000 shares of its common stock and warrants to purchase 50,000,000 shares of its common stock at a price to the public